Alumis

Our CEO, Martin Babler, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 10:40 EST today. Catch the presentation live at: https://lnkd.in/eFWyJx-J

Late-breaking data presented at #AAD2025 demonstrate ESK-001’s robust clinical responses for the potential treatment of psoriasis through week 52, including patients’ reported symptoms and quality of life. Learn more: https://lnkd.in/e6Y--Q99

We're shaking things up in psoriasis at #AAD2025! Stop by BOOTH #952 for a milkshake and to learn about our next-generation TYK2 inhibitor, the unmet needs we aim to address, and Alumis. We hope to see you there!

On the heels of #ACTRIMSForum and at the start of #MSAwarenessMonth, we are feeling inspired by the innovation occurring within the multiple sclerosis community and proud to contribute to discussions that can foster advancements in clinical care. If you missed our poster presentations, you can find them here: https://bit.ly/4ePa5JT

Exciting News: Alumis will give four data presentations, including a late-breaker oral presentation of our 52-week data from the open-label extension period of the Phase 2 STRIDE clinical trial evaluating ESK-001 in patients with psoriasis, at #AAD2025 from March 7 to 11, 2025, in Orlando, Florida. We also announced the company has accelerated the expected topline Phase 3 clinical data milestone to the first quarter of 2026. Read more: https://lnkd.in/efKppwKg

The Alumis team is on the ground at #ACTRIMSForum 2025 excited for tomorrow’s poster presentations that support our plan to begin a Phase 2 clinical trial of oral TYK2 inhibitor A-005 in patients with multiple sclerosis in the second half of this year. Learn more: https://lnkd.in/gsnUVYvM Poster Session 2 Presentations: - P352: A-005, a Selective Oral Brain Penetrant TYK2 Inhibitor, Modulates Astrocytes and Microglia  - P335: Safety, Tolerability, and Pharmacokinetics of A-005: A Selective Brain-Penetrant TYK2 Inhibitor for CNS Inflammatory Diseases in Healthy Volunteers Following Single and Multiple Ascending Doses 

Our CEO, Martin Babler, will be presenting today at the Oppenheimer 35th Annual Healthcare Life Sciences Conference at 3:20 pm ET. Catch the presentation live to learn more about our highly differentiated late-stage portfolio of investigational treatments for immune-mediated diseases: https://lnkd.in/eV5S5qHj #OPCOLifeSciences

We are excited to announce our merger with ACELYRIN, INC. This is an important step forward for Alumis to advance our highly differentiated late-stage portfolio to improve the lives of patients with immune-mediated diseases. Read more here and join our webcast today at 5:00 pm ET: https://lnkd.in/eccQBH4Q

Congratulations to Jack Danilkowicz, who joins Alumis as Chief Commercial Officer and brings extensive experience successfully planning and executing commercial strategies for global biopharmaceutical companies, and to Sara Ramseyer Klein on her promotion to Chief Legal Officer. Learn more about these exciting key leadership team appointments here:https://lnkd.in/eE9jxqDn

The Alumis team is on the ground at Maui Derm Hawaii! Make sure to stop by our booth this week and check out our poster presentations to learn about ESK-001, an oral tyrosine kinase 2 (TYK2) inhibitor currently being evaluated in the Phase 3 ONWARD clinical program for the treatment of moderate-to-severe plaque psoriasis. For more information: https://bit.ly/3C5oyE5